Ross A. Soo

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Ross A. Soo

Dec 29, 2024, 07:46 | Blog

Erman Akkus: Top 4 articles of JCO ASCO in 2024

Erman Akkus, Medical oncology fellow at the Ankara University, shared a post on X: “Top…

Nov 25, 2024, 17:53 | Insight

Safety of Lorlatinib in ALK positive NSCLC

Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber and Harvard Medical School, shared a recent article…

Nov 24, 2024, 13:36 | Insight

Eric K. Singhi: Is it time to universally prescribe 1L lorlatinib for all?

Eric K. Singhi, Assistant Professor in the Department of General Oncology within the Division of…

Aug 19, 2024, 16:16 | Insight

Capmatinib and nazartinib shows promise in EGFR-mutated Lung Cancer resistant to prior treatments

EGFR Positive UK shared a post on X: "Capmatinib and nazartinib shows promise in patients with…

Jun 2, 2024, 22:20 | Insight

Sylvester Cancer study on immunotherapy drug durvalumab shows limited access globally due to cost constraints

Access to Targeted Lung Cancer Drug Is Cost-Prohibitive Globally Many countries with national healthcare systems…

All: 5 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023